FDA Approves Device for Pancreas Care - Takeaways - MDSpire

FDA Approves Device for Pancreas Care

In the phase 3 PANOVA-3 trial, adding Tumor Treating Fields therapy to gemcitabine and nab-paclitaxel was associated with improved overall survival and delayed pain progression in adults with locally advanced pancreatic cancer.

  • By

  • Kathryn Wighton

  • February 12, 2026

  • 3 min

Share

  • 1

    The FDA approved Optune Pax for adult patients with locally advanced pancreatic cancer, used with gemcitabine and nab-paclitaxel.

  • 2

    Approval was based on the PANOVA-3 trial, which showed improved overall survival and prolonged time to pain progression.

  • 3

    Optune Pax is a noninvasive device delivering Tumor Treating Fields through adhesive arrays on the abdomen.

  • 4

    The device was well tolerated, with most adverse events being mild and no new safety signals identified.

  • 5

    This marks the first new FDA-approved treatment for locally advanced pancreatic cancer in nearly 30 years.

Original Source(s)

FDA Approves Device for Pancreas Care

  • by Kathryn Wighton

  • February 12, 2026

Related Content

3 Medical Routines That Older People May Not Need

“The treatment may be more burdensome than the condition itself."

Rare Ebola Strain Sparks Global Alert

CDC urges travelers returning from Central Africa to monitor for Ebola symptoms for 21 days.

Top 10 States with the Lowest Costs for Running a Medical Practice

These 10 states posted some of the lowest 2026 Medicare practice expense GPCI among states that CMS treats as a single statewide locality, with broader price levels and selected malpractice or tax indicators adding context.